m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05487
|
[1] | |||
m6A modification
LINC00470
LINC00470
METTL3
Methylation
 : m6A sites
Direct
Enhancement
Non-coding RNA
LINC00470
PTEN
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Long intergenic non-protein coding RNA 470 (LINC00470) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Long intergenic non-protein coding RNA 470 (LINC00470) | LncRNA | View Details | ||
| Regulated Target | Mutated in multiple advanced cancers 1 (PTEN) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | The molecular mechanism underlying the effect of Long intergenic non-protein coding RNA 470 (LINC00470) on chronic myelocytic leukaemia by reducing the Mutated in multiple advanced cancers 1 (PTEN) stability via RNA methyltransferase METTL3, thus leading to the inhibition of cell autophagy while promoting chemoresistance in CML. | ||||
| Responsed Disease | Chronic myeloid leukaemia | ICD-11: 2B33.2 | |||
| Pathway Response | PI3K-Akt signaling pathway | hsa04151 | |||
| Cell Process | Cell autophagy | ||||
In-vitro Model |
KCL-22 | Chronic myelogenous leukemia | Homo sapiens | CVCL_2091 | |
| K-562 | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 | ||
| In-vivo Model | In the control mice or ADR mice group, the parental or chemo-resistant K562 cells were infected with LV-shCtrl. In the ADR + shLINC00470 group, the chemo-resistant K562 cells were infected with LV- shLINC00470. These cells were injected, respectively, into these 5-week-old mice subcutaneously. | ||||